Comment: Epoetin Alfa Versus Darbepoetin Alfa for Cancer Patients with Treatment-Related Anemia

Cersosimo R , Jacobson D. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Ann Pharmacother 2006;40:58–65. Epub 6 Dec 2005. DOI 10.1345/aph.1G042

Product information. Procrit (epoetin alfa). Raritan, NJ: Ortho Biotech Products, LP, 2005.

Schwartzberg LS , Yee LK , Senecal FM . A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9:696–707.

Waltzman R , Croot C , Justice GR , Fesen MR , Charu V , Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005;10:642–50.

Glaspy J , Berg R , Tomita D , Rossi G , Vadhan-Raj S. Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 μg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (QW) in patients with chemotherapy-induced anemia (CIA) (abstract 8125). Presented at: American Society of Clinical Oncology Annual Meeting, Orlando, FL, May 14–17, 2005.

Lefebvre P , Gosselin A , Fastenau JM , McKenzie RS , Duh MS . Treatment patterns and frequency of outpatient visits in adults with cancer receiving erythropoietic agents in a managed care organization (poster). Presented at: Academy of Managed Care Pharmacy 17th Annual Meeting and Showcase, Denver, CO, April 20–23, 2005.